Human colon cancer cells deficient in DCC produce abnormal transcripts in progression of carcinogenesis

S. Huerta, E. S. Srivatsan, N. Venkatasan, E. H. Livingston

Research output: Contribution to journalArticle

10 Citations (Scopus)

Abstract

Expressive loss of the tumor suppressor deleted in colon cancer (DCC) may be superior to lymph node status in predicting patient survival for intermediate stage colon cancer. A polymerase chain reaction (PCR)-based method for detecting DCC would be ideal as a prognostic indicator. DCC is an alternatively spliced molecule; thus, reliability of a PCR test for DCC will depend on amplifying only those regions of the molecule that are lost in the progression of colon cancer. For this reason, we studied a colon cancer cell line model at different stages of tumor progression to determine the alternative splice pattern for DCC. A commercially available colon cancer cell line system at different stages of tumor progression was used to identify which DCC exons are lost by western blot analysis, PCR, and RT-PCR techniques. Colon cancers express abnormal DCC transcripts. The proximal and distal exons are present (exons 2 and 28-29). Exons located in the center of the molecule are absent (6-7 and 18-23). This correlated to DCC protein loss in the cell lines. For clinical utility as a disease marker, exons in the middle portion of the DCC molecule that are spliced out should be utilized. Amplification of the proximal and distal regions will result in falsely concluding that DCC is present when its protein product is not expressed.

Original languageEnglish (US)
Pages (from-to)1884-1891
Number of pages8
JournalDigestive Diseases and Sciences
Volume46
Issue number9
DOIs
StatePublished - 2001

Fingerprint

Colonic Neoplasms
Carcinogenesis
Exons
Polymerase Chain Reaction
Cell Line
Neoplasms
Proteins
Lymph Nodes
Western Blotting

Keywords

  • Colon cancer
  • DCC
  • SW480
  • SW620

ASJC Scopus subject areas

  • Gastroenterology

Cite this

Human colon cancer cells deficient in DCC produce abnormal transcripts in progression of carcinogenesis. / Huerta, S.; Srivatsan, E. S.; Venkatasan, N.; Livingston, E. H.

In: Digestive Diseases and Sciences, Vol. 46, No. 9, 2001, p. 1884-1891.

Research output: Contribution to journalArticle

Huerta, S. ; Srivatsan, E. S. ; Venkatasan, N. ; Livingston, E. H. / Human colon cancer cells deficient in DCC produce abnormal transcripts in progression of carcinogenesis. In: Digestive Diseases and Sciences. 2001 ; Vol. 46, No. 9. pp. 1884-1891.
@article{cd3c16e6ecea459daff5cf3617c5373c,
title = "Human colon cancer cells deficient in DCC produce abnormal transcripts in progression of carcinogenesis",
abstract = "Expressive loss of the tumor suppressor deleted in colon cancer (DCC) may be superior to lymph node status in predicting patient survival for intermediate stage colon cancer. A polymerase chain reaction (PCR)-based method for detecting DCC would be ideal as a prognostic indicator. DCC is an alternatively spliced molecule; thus, reliability of a PCR test for DCC will depend on amplifying only those regions of the molecule that are lost in the progression of colon cancer. For this reason, we studied a colon cancer cell line model at different stages of tumor progression to determine the alternative splice pattern for DCC. A commercially available colon cancer cell line system at different stages of tumor progression was used to identify which DCC exons are lost by western blot analysis, PCR, and RT-PCR techniques. Colon cancers express abnormal DCC transcripts. The proximal and distal exons are present (exons 2 and 28-29). Exons located in the center of the molecule are absent (6-7 and 18-23). This correlated to DCC protein loss in the cell lines. For clinical utility as a disease marker, exons in the middle portion of the DCC molecule that are spliced out should be utilized. Amplification of the proximal and distal regions will result in falsely concluding that DCC is present when its protein product is not expressed.",
keywords = "Colon cancer, DCC, SW480, SW620",
author = "S. Huerta and Srivatsan, {E. S.} and N. Venkatasan and Livingston, {E. H.}",
year = "2001",
doi = "10.1023/A:1010626929411",
language = "English (US)",
volume = "46",
pages = "1884--1891",
journal = "Digestive Diseases and Sciences",
issn = "0163-2116",
publisher = "Springer New York",
number = "9",

}

TY - JOUR

T1 - Human colon cancer cells deficient in DCC produce abnormal transcripts in progression of carcinogenesis

AU - Huerta, S.

AU - Srivatsan, E. S.

AU - Venkatasan, N.

AU - Livingston, E. H.

PY - 2001

Y1 - 2001

N2 - Expressive loss of the tumor suppressor deleted in colon cancer (DCC) may be superior to lymph node status in predicting patient survival for intermediate stage colon cancer. A polymerase chain reaction (PCR)-based method for detecting DCC would be ideal as a prognostic indicator. DCC is an alternatively spliced molecule; thus, reliability of a PCR test for DCC will depend on amplifying only those regions of the molecule that are lost in the progression of colon cancer. For this reason, we studied a colon cancer cell line model at different stages of tumor progression to determine the alternative splice pattern for DCC. A commercially available colon cancer cell line system at different stages of tumor progression was used to identify which DCC exons are lost by western blot analysis, PCR, and RT-PCR techniques. Colon cancers express abnormal DCC transcripts. The proximal and distal exons are present (exons 2 and 28-29). Exons located in the center of the molecule are absent (6-7 and 18-23). This correlated to DCC protein loss in the cell lines. For clinical utility as a disease marker, exons in the middle portion of the DCC molecule that are spliced out should be utilized. Amplification of the proximal and distal regions will result in falsely concluding that DCC is present when its protein product is not expressed.

AB - Expressive loss of the tumor suppressor deleted in colon cancer (DCC) may be superior to lymph node status in predicting patient survival for intermediate stage colon cancer. A polymerase chain reaction (PCR)-based method for detecting DCC would be ideal as a prognostic indicator. DCC is an alternatively spliced molecule; thus, reliability of a PCR test for DCC will depend on amplifying only those regions of the molecule that are lost in the progression of colon cancer. For this reason, we studied a colon cancer cell line model at different stages of tumor progression to determine the alternative splice pattern for DCC. A commercially available colon cancer cell line system at different stages of tumor progression was used to identify which DCC exons are lost by western blot analysis, PCR, and RT-PCR techniques. Colon cancers express abnormal DCC transcripts. The proximal and distal exons are present (exons 2 and 28-29). Exons located in the center of the molecule are absent (6-7 and 18-23). This correlated to DCC protein loss in the cell lines. For clinical utility as a disease marker, exons in the middle portion of the DCC molecule that are spliced out should be utilized. Amplification of the proximal and distal regions will result in falsely concluding that DCC is present when its protein product is not expressed.

KW - Colon cancer

KW - DCC

KW - SW480

KW - SW620

UR - http://www.scopus.com/inward/record.url?scp=0034849942&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0034849942&partnerID=8YFLogxK

U2 - 10.1023/A:1010626929411

DO - 10.1023/A:1010626929411

M3 - Article

C2 - 11575440

AN - SCOPUS:0034849942

VL - 46

SP - 1884

EP - 1891

JO - Digestive Diseases and Sciences

JF - Digestive Diseases and Sciences

SN - 0163-2116

IS - 9

ER -